Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I
Open Access
- 1 April 2016
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 24 (4), 719-725
- https://doi.org/10.1038/mt.2015.224
Abstract
No abstract availableKeywords
Funding Information
- Ministerio de Ciencia e Innovación
This publication has 17 references indexed in Scilit:
- High resolution crystal structure of rat long chain hydroxy acid oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1, 2, 3-thiadiazole. Implications for inhibitor specificity and drug designBiochimie, 2012
- Pharmacological small molecules for the treatment of lysosomal storage disordersExpert Opinion on Investigational Drugs, 2010
- Structure of human glycolate oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazoleActa Crystallographica Section F Structural Biology and Crystallization Communications, 2009
- Active Site and Loop 4 Movements within Human Glycolate Oxidase: Implications for Substrate Specificity and Drug DesignBiochemistry, 2008
- Hydroxyproline ingestion and urinary oxalate and glycolate excretionKidney International, 2006
- Alanine–glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transferProceedings of the National Academy of Sciences, 2006
- Glycolate and glyoxylate metabolism in HepG2 cellsAmerican Journal of Physiology-Cell Physiology, 2004
- GLYOXYLATE SYNTHESIS, AND ITS MODULATION AND INFLUENCE ON OXALATE SYNTHESISJournal of Urology, 1998
- Three‐dimensional structures of glycolate oxidase with bound active‐site inhibitorsProtein Science, 1997
- Inhibition of oxalate synthesis: In vitro studies using analogues of oxalate and glycolateBiochemical Medicine, 1972